|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
66,383,000 |
Market
Cap: |
1.33(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$16.53 - $28.72 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 2 |
Insider 6 Months : 2 |
Insider 3/6 Months : 4.3 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
53 |
53 |
53 |
53 |
Total Buy Value |
$1,013 |
$1,013 |
$1,013 |
$1,013 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
101,351 |
146,351 |
179,848 |
214,693 |
Total Sell Value |
$2,152,463 |
$3,094,133 |
$3,971,419 |
$5,040,525 |
Total People Sold |
5 |
5 |
5 |
6 |
Total Sell Transactions |
10 |
11 |
12 |
27 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Desjarlais John R |
Sr. V.P., Research & CSO |
|
2016-12-05 |
4 |
OE |
$0.59 |
$69,467 |
D/D |
117,741 |
146,381 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2016-09-28 |
4 |
AS |
$25.17 |
$253,475 |
D/D |
(10,000) |
0 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2016-09-28 |
4 |
OE |
$0.59 |
$5,900 |
D/D |
10,000 |
10,000 |
|
- |
|
Ronin Capital, Llc |
10% Owner |
|
2016-09-27 |
4 |
S |
$25.86 |
$795,688 |
I/I |
(30,775) |
5,055,561 |
|
- |
|
Ronin Capital, Llc |
10% Owner |
|
2016-09-26 |
4 |
S |
$25.07 |
$55,781 |
I/I |
(2,225) |
5,086,336 |
|
- |
|
Ronin Capital, Llc |
10% Owner |
|
2016-09-23 |
4 |
S |
$25.34 |
$177,345 |
I/I |
(7,000) |
5,088,561 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2016-09-02 |
4 |
S |
$21.06 |
$210,641 |
D/D |
(10,000) |
0 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2016-09-02 |
4 |
OE |
$0.59 |
$5,900 |
D/D |
10,000 |
10,000 |
|
- |
|
Dahiyat Bassil I |
President and CEO |
|
2016-08-30 |
4 |
S |
$21.80 |
$872,028 |
D/D |
(40,000) |
341,128 |
|
- |
|
Ronin Capital, Llc |
10% Owner |
|
2016-08-26 |
4 |
S |
$21.48 |
$523,059 |
I/I |
(24,351) |
5,095,561 |
|
- |
|
Kuch John J |
Vice President, Finance |
|
2016-08-24 |
4 |
S |
$21.76 |
$548,813 |
D/D |
(25,000) |
67,078 |
|
- |
|
Kuch John J |
Vice President, Finance |
|
2016-08-24 |
4 |
OE |
$11.05 |
$158,568 |
D/D |
14,350 |
92,078 |
|
- |
|
Desjarlais John R |
Sr. V.P., Research & CSO |
|
2016-08-23 |
4 |
S |
$21.73 |
$354,065 |
D/D |
(16,294) |
28,640 |
|
- |
|
Ronin Capital, Llc |
10% Owner |
|
2016-08-23 |
4 |
S |
$21.71 |
$802,510 |
I/I |
(36,965) |
5,119,912 |
|
- |
|
Ronin Capital, Llc |
10% Owner |
|
2016-08-22 |
4 |
S |
$21.74 |
$1,301,122 |
I/I |
(59,863) |
5,156,877 |
|
- |
|
Dahiyat Bassil I |
President and CEO |
|
2016-08-16 |
4 |
AS |
$22.06 |
$1,012,317 |
D/D |
(45,886) |
381,128 |
|
- |
|
Dahiyat Bassil I |
President and CEO |
|
2016-08-16 |
4 |
OE |
$0.59 |
$67,681 |
D/D |
114,714 |
427,014 |
|
- |
|
Ronin Capital, Llc |
10% Owner |
|
2016-08-15 |
4 |
S |
$23.06 |
$230,550 |
I/I |
(10,000) |
5,216,740 |
|
- |
|
Carter Bruce L A |
Director |
|
2016-08-15 |
4 |
S |
$22.67 |
$77,074 |
D/D |
(3,400) |
6,600 |
|
- |
|
Carter Bruce L A |
Director |
|
2016-08-11 |
4 |
OE |
$0.59 |
$5,900 |
D/D |
10,000 |
10,000 |
|
- |
|
Ronin Capital, Llc |
10% Owner |
|
2016-08-11 |
4 |
S |
$22.01 |
$220,100 |
I/I |
(10,000) |
5,226,740 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2016-08-10 |
4 |
AS |
$21.83 |
$54,576 |
D/D |
(2,500) |
0 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2016-08-10 |
4 |
OE |
$0.59 |
$1,475 |
D/D |
2,500 |
2,500 |
|
- |
|
Ronin Capital, Llc |
10% Owner |
|
2016-08-10 |
4 |
S |
$21.73 |
$228,113 |
I/I |
(10,500) |
5,236,740 |
|
- |
|
Ronin Capital, Llc |
10% Owner |
|
2016-08-09 |
4 |
S |
$21.88 |
$218,800 |
I/I |
(10,000) |
5,247,240 |
|
- |
|
312 Records found
|
|
Page 9 of 13 |
|
|